Did the company provide guidance for Q3 and full‑year 2025 revenue and earnings?

Answer: No – Codexis (CDXS) did not issue any forward‑looking guidance for either Q3 2025 or the full‑year 2025 in its second‑quarter release. The filing simply reported Q2 revenue of $15.3 million (beating the $14.1 million consensus) and provided the usual balance‑sheet and cash‑flow details, but it omitted any projection of future revenue or earnings.

Trading implications

• Fundamentals: The beat‑and‑raise in Q2 suggests the business is still gaining traction, yet the lack of guidance leaves the upside potential for the next quarter and FY 2025 ambiguous. Without a revenue or earnings outlook, the market will price the stock on the back of the Q2 beat and any macro or sector cues (e.g., biotech funding trends, enzyme‑technology demand).
  
• Technical: CDXS has been trading in a tight range around its recent support at ~ $1.20‑$1.30. The Q2 beat could spark a short‑term bounce toward the $1.40 resistance, but the absence of guidance may cap the rally, prompting a quick retracement to the prior support zone.
  
• Actionable view: Consider a short‑term, momentum‑based play – buy on a breakout above $1.40 with a stop just below $1.30, targeting a modest 5‑8 % upside. For longer‑term positioning, hold off on adding to a position until the company releases Q3 guidance (likely in the next earnings call) or provides a FY 2025 outlook, which will be the key driver for a more definitive valuation.